Clinical significance of serum thrombospondin-4 for interventional restenosis in diabetes patients complicated by lower extremity arteriosclerosis obliterans

doi:10.4239/wjd.124271

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(11)

(9)

(0)

(40)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Oct 15, 2026; 17(10): 124271
Published online Oct 15, 2026. doi: 10.4239/wjd.124271

Table 2 Univariate analysis of postoperative restenosis in the training cohort, n (%)/mean ± SD

Variables	Training cohort		t/Z/χ²	P value
Variables	Restenosis (n = 45)	Non-restenosis (n = 55)	t/Z/χ²	P value
Male	30 (66.70)	32 (58.20)	0.756	0.414
Age (year)	75.00 (66.50, 82.00)	70.00 (63.00, 74.00)	-3.343	0.001^b
Diabetes duration (year)	11.70 ± 7.66	11.75 ± 7.28	-0.030	0.976
Coronary heart disease	13 (28.90)	14 (25.50)	0.148	0.822
Cerebral infarction	23 (51.10)	22 (40.00)	1.235	0.315
Smoking	24 (53.30)	19 (34.50)	3.564	0.070
Drinking	18 (40.00)	17 (30.90)	0.899	0.402
Fontaine stage			-2.839	0.005^b
II	11 (24.40)	28 (50.90)
III	11 (24.40)	12 (21.80)
IV	23 (51.10)	15 (27.30)
BMI (kg/m²)	23.20 ± 4.21	23.06 ± 3.81	0.170	0.865
Hb (g/L)	125.02 ± 20.57	121.00 ± 22.84	0.916	0.362
ALB (g/L)	38.26 ± 4.97	38.86 ± 3.95	-0.676	0.500
ALT (U/L)	14.00 (10.50, 23.00)	15.00 (12.00, 22.00)	-0.285	0.778
AST (U/L)	16.00 (13.00, 20.00)	17.00 (14.00, 22.00)	-0.198	0.845
TBIL (μmol/L)	9.97 (6.69, 13.60)	9.40 (7.40, 13.22)	-0.461	0.648
Scr (μmol/L)	76.00 (64.00, 123.00)	74.00 (57.00, 93.00)	-0.142	0.887
FPG (mmol/L)	7.59 (6.16, 10.26)	6.64 (5.71, 8.30)	-1.559	0.120
HbA1c (%)	8.19 ± 1.55	7.39 ± 1.53	2.606	0.011^a
TC (mmol/L)	4.36 ± 1.59	4.11 ± 1.26	0.874	0.384
TG (mmol/L)	1.23 (0.93, 1.94)	1.31 (1.00, 1.64)	-0.215	0.832
LDL-C (mmol/L)	3.03 ± 0.71	2.21 ± 0.73	5.618	< 0.001^b
HDL-C (mmol/L)	0.96 ± 0.30	0.96 ± 0.20	-0.023	0.982
FIB (g/L)	4.31 (3.46, 5.30)	3.79 (3.06, 5.26)	-1.022	0.309
D-D (mg/L)	0.58 (0.33, 0.99)	0.42 (0.23, 0.69)	-2.450	0.014^a
hs-CRP (mg/L)	3.43 (2.59, 3.84)	1.75 (1.20, 2.70)	-4.958	< 0.001^b
TSP-4 (ng/mL)	76.60 (60.67, 92.54)	48.70 (23.30, 65.99)	-5.020	< 0.001^b

^aP < 0.05.

^bP < 0.01.

Quantitative data are expressed as mean ± SD or median (IQR), analyzed using the t test or Mann-Whitney U test. Categorical data are expressed as n (%), analyzed using the χ² test or Mann-Whitney U test. BMI: Body mass index; Hb: Hemoglobin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; Scr: Serum creatinine; FPG: Fasting plasma glucose; HbA1c: Glycated hemoglobin A1c; TC: Total cholesterol; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; FIB: Fibrinogen; D-D: D-dimer; hs-CRP: High-sensitivity C-reactive protein; TSP-4: Thrombospondin-4.

Full Size Table

Citation: Hu D, Lin XY, Zhao TQ, Ji H, Chen MW, Zhao XT. Clinical significance of serum thrombospondin-4 for interventional restenosis in diabetes patients complicated by lower extremity arteriosclerosis obliterans. World J Diabetes 2026; 17(10): 124271
URL: https://www.wjgnet.com/1948-9358/full/v17/i10/124271.htm
DOI: https://dx.doi.org/10.4239/wjd.124271

Hu D, Lin XY, Zhao TQ, Ji H, Chen MW, Zhao XT. Clinical significance of serum thrombospondin-4 for interventional restenosis in diabetes patients complicated by lower extremity arteriosclerosis obliterans. World J Diabetes 2026; 17(10): 124271 [DOI: 10.4239/wjd.124271]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.